Tumor response following neoadjuvant MR-guided single ablative dose partial breast irradiation.
To assess the pathologic and radiologic response in low-risk breast cancer patients, treated with MR-guided neoadjuvant partial breast irradiation (NA-PBI), and to evaluate toxicity and patient reported outcomes (PROs). For this single-arm prospective trial, women with unifocal, non-lobular tumors, with a maximum diameter of 20mm (50-70 years) or 30mm (≥70 years), and tumor-negative sentinel node(s) were eligible. Patients were treated with single ablative dose NA-PBI followed by breast conserving surgery after an interval of six to eight months. Target volumes were defined on radiotherapy planning CT-scan and additional MRI. Prescribed doses to gross tumor volume (GTV) and clinical target volume (GTV plus 20mm margin) were 20Gy and 15Gy, respectively. Primary outcome was pathologic complete response (pCR). Secondary outcomes were radiologic response (on MRI), toxicity (CTCAE), PROs (EORTC QLQ-BR23 and Hospital Anxiety and Depression Scale), and cosmesis (assessed by patient, radiation oncologist and BCCT.core software). 36 patients were treated with NA-PBI, pCR was reported in 15 patients (42%;95%CI, 26%-59%). Radiologic complete response was observed in 15 patients, 10 of whom had pCR (positive predictive value 67%;95%CI, 39%-87%). After a median follow-up of 21 months (range 12-41), all patients experienced grade 1 fibrosis in treated breast volume. Transient grade 2 and 3 toxicity was observed in 31% and 3% of patients, respectively. Local recurrences were absent. No deterioration in PROs or cosmetic results was observed. NA-PBI has the potential to induce pCR in a substantial proportion of patients with acceptable toxicity. This treatment seems a feasible alternative to standard postoperative irradiation, and could even result in postponement or omission of surgery, if pCR can be accurately predicted in selected low-risk patients.